Medtronic, Bos Sci ordered to pay J&J about $1.2B for stent patents

The U.S. District Court in Delaware has awarded Johnson & Johnson (J&J) damages totaling $406.7 million and pre-judgment interest totaling $296 million from Boston Scientific and $521 million from Medtronic, in a case involving a stent patent owned by J&J.

Boston Scientific said it will appeal the judgment.

On Sept. 15, the U.S. Delaware District Court Judge Sue Robinson Monday granted J&J’s subsidiary, Cordis, a motion for final judgment against Boston Scientific and Medtronic, in their cases involving Cordis’ Palmaz balloon expandable stent patent.

The case relates to GFX and Microstent II from the Minneapolis-based Medtronic and the NIR stent from the Natick, Mass.-based Boston Scientific.

The original suit was filed in 1997, and Boston Scientific said it has not sold the NIR stent since 2004.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup